[Metabolic effect of lipostabil-forte].
Effects of lipostabil-forte containing unsaturated fatty acids on serum lipid concentrations, plasma and erythrocyte lipid and phospholipid fractions, immunoreactive insulin and thyroidal hormone levels were studied in 30 patients with coronary heart disease. During the therapy of all the patients within 1 month and occasionally 3 and 6 months, there was a statistically significant reduction in serum triglycerides, an increase in relative erythrocyte phospholipid levels and in plasma and erythrocyte phosphotylcholine, as well as reversal of hyperinsulinemia and improvement of thyroid function.
Bobkova
V I
VI
Lokshina
L I
LI
Korsunskiĭ
V N
VN
Tananova
G V
GV
D000368:Aged; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000150:complications; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000209:etiology; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000627:therapeutic use*; D010743:Phospholipids / Q000097:blood; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D010713:Phosphatidylcholines; D010743:Phospholipids; D014280:Triglycerides; C005152:lipostabil; D002784:Cholesterol
Metabolicheskiĭ éffekt lipostabila-forte.